Trial · NCT01182675
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
NCT01182675, Phase 2, Terminated, University of California, San Francisco; results first posted 2014-11-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim. Trials, record NCT01182675. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01182675
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
- NCT number
- NCT01182675
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- First posted
- 2010-08-17
- Last updated
- 2018-07-31
- Results first posted
- 2014-11-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Engraftment of Donor B-cells in Blood by STR Testing | 1 Year | Number of participants in whom donor B cells were detected in the patient's blood after HSCT. |
| Secondary | Incidence of Acute GVHD | 100 Days | |
| Secondary | Incidence of Chronic GVHD | 2 Years | |
| Secondary | Percentage of Patients Who Become Independent From Regular IVIG Infusion | 2 Years | Based on B-cell function assays from the patient's blood, we will be able to determine if patients are able to successfully discontinue IVIG infusions. |
| Secondary | Number of Patients With Engraftment of Donor Stem Cells in Bone Marrow by STR Testing | 1 Year | We will measure whether we are able to detect donor stem cells in the patient's bone marrow after HSCT. |
| Secondary | Number of Patients Who Achieve Engraftment of Donor T-cells in Blood by STR Testing | 1 Year | We will measure whether we are able to detect donor T-cells in the patient's blood after HSCT. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Engraftment of Donor B-cells in Blood by STR Testing | 1 Year | No patients with T-cell Graft Resistant SCID were enrolled during the time the trial was open. | participants | NUMBER |
| SECONDARY | Incidence of Acute GVHD | 100 Days | No patients with T-cell Graft Resistant SCID were enrolled during the time the trial was open. | participants | NUMBER |
| SECONDARY | Incidence of Chronic GVHD | 2 Years | No patients with T-cell Graft Resistant SCID were enrolled during the time the trial was open. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Patients Who Become Independent From Regular IVIG Infusion | 2 Years | No patients with T-cell Graft Resistant SCID were enrolled during the time the trial was open. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Engraftment of Donor Stem Cells in Bone Marrow by STR Testing | 1 Year | No patients with T-cell Graft Resistant SCID were enrolled during the time the trial was open. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients Who Achieve Engraftment of Donor T-cells in Blood by STR Testing | 1 Year | No patients with T-cell Graft Resistant SCID were enrolled during the time the trial was open. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Engraftment of Donor B-cells in Blood by STR Testing | T-cell Graft Permissive SCID | 0 | participants | ||
| Incidence of Acute GVHD | T-cell Graft Permissive SCID | 1 | participants | ||
| Incidence of Chronic GVHD | T-cell Graft Permissive SCID | 1 | Participants | ||
| Percentage of Patients Who Become Independent From Regular IVIG Infusion | T-cell Graft Permissive SCID | 0 | Participants | ||
| Number of Patients With Engraftment of Donor Stem Cells in Bone Marrow by STR Testing | T-cell Graft Permissive SCID | 0 | Participants | ||
| Number of Patients Who Achieve Engraftment of Donor T-cells in Blood by STR Testing | T-cell Graft Permissive SCID | 7 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | T-cell Graft Permissive SCID | 7 | |
| Overall Study | STARTED | T-cell Graft Resistant SCID | 0 | |
| Overall Study | COMPLETED | T-cell Graft Permissive SCID | 7 | |
| Overall Study | COMPLETED | T-cell Graft Resistant SCID | 0 | |
| Overall Study | NOT COMPLETED | T-cell Graft Permissive SCID | 0 | |
| Overall Study | NOT COMPLETED | T-cell Graft Resistant SCID | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | T-cell Graft Permissive SCID | 0 | 7 |
| Total, all-cause mortality | T-cell Graft Resistant SCID | 0 | 0 |
| Total, other adverse events | T-cell Graft Permissive SCID | 0 | 7 |
| Total, other adverse events | T-cell Graft Resistant SCID | 0 | 0 |
| Total, serious adverse events | T-cell Graft Permissive SCID | 0 | 7 |
| Total, serious adverse events | T-cell Graft Resistant SCID | 0 | 0 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01182675
GET https://conductscience.org/api/trials/v1/NCT01182675/registered